Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02651662 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
A Phase 1 study of Relapsed/Refractory Aggressive B-Cell Lymphoma, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
- 20
- Study locations
NCT02651662: Active Phase 1 study of Relapsed/Refractory Aggressive B-Cell Lymphoma, sponsored by Regeneron Pharmaceuticals.
NCT02651662 is a Phase 1 study of Relapsed/Refractory Aggressive B-Cell Lymphoma that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 105 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02651662, a Phase 1 study of Relapsed/Refractory Aggressive B-Cell Lymphoma, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810). The study is focused on patients who have relapse/refractory aggressive B-cell lymphoma. The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose regimen for the combination with odronextamab. This study is also looking at several other research questions, including: * What side effects may happen from taking the study drugs * How effective the study drugs are against the disease * How much study drug is in the blood at different times * Whether the body makes substances or protein called antibodies against the study drugs (that could make the drugs less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG cemiplimab
- DRUG odronextamab
Study Locations (20)
Other
- Uniklinikum Salzburg (LKH) Universitatsklinik fur Innere Medizin III - Salzburg
- Medical University Vienna - Vienna
- University Hospital Frankfurt - Frankfurt am Main
- Universitatsklinikum Jena - Jena
- Universitatsklinikum Schleswig-Holstein, Campus Kiel - Kiel
- Soroka - Beersheba
- Hadassah Medical Center - Jerusalem
- Chaim Sheba Medical Center - Ramat Gan
- Tel Aviv Sourasky Medical Center - Tel Aviv
- Pratia Onkologia Katowice - Katowice
- Copernicus Memorial Hospital - Lodz
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa - Warsaw
Massachusetts
- Dana Farber/Harvard Cancer Center - PO box 849168 - Boston
- Harvard Medical School - Beth Israel Deaconess Medical Center - Boston
Maryland
- Johns Hopkins University - Baltimore
Michigan
- Cancer & Hematology Centers of Western Michigan - Grand Rapids
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Malopolska
- Pratia MCM Krakow - Krakow
Pomeranian Voivodeship
- Uniwersyteckie Centrum Kliniczne - Gdansk
Cantabria
- Hospital Universitario Marques de Valdecilla - Santander
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2016-01-11 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 1 |
What the registry record for NCT02651662 still lists
NCT02651662 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% higher).
The record links to 1 condition, with Relapsed/Refractory Aggressive B-Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which cemiplimab is the first listed.
NCT02651662 names 20 study sites across 8 states, led by Other, Massachusetts, Maryland.
Frequently Asked Questions
What is clinical trial NCT02651662 about?
NCT02651662 is a clinical study titled "A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies". This study is researching a combination of 2 experimental drugs, referred to as "study drugs", called odronextamab (also known as REGN1979) and cemiplimab (also known as REGN2810). The study is focused on patients who have relapse/refractory aggressive B-cell lymphoma. The aim of the study is to see...
What is the current status of trial NCT02651662?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2016-01-11. Estimated completion is 2026-05-31.
What conditions does trial NCT02651662 study?
This clinical trial studies the following conditions: Relapsed/Refractory Aggressive B-Cell Lymphoma.
What interventions are being tested in trial NCT02651662?
The interventions under investigation include: cemiplimab (DRUG), odronextamab (DRUG).
Who is sponsoring clinical trial NCT02651662?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02651662 being conducted?
This trial has 20 study locations across Maryland, Massachusetts, Michigan, Ohio, Malopolska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02651662's enrollment target sits among peer trials
105 533rd of 2000 higher than 1,465 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI